bay-k-8644 has been researched along with Auricular Fibrillation in 5 studies
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester: A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool.
Bay-K-8644 : A racemate comprising equimolar amounts of (R)- and (S)-Bay-K-8644
methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate : A pentasubstituted dihydropyridine carrying methoxycarbonyl, 2-(trifluoromethyl)phenyl and nitro substituents at positions 3, 4 and 5 respectively as well as two methyl substituents at positions 2 and 6.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Atrial contractile dysfunction after short-term atrial fibrillation is reduced by the calcium antagonist verapamil, which suggests that transsarcolemmal calcium influx contributed to this dysfunction." | 7.69 | Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. ( Aksnes, G; Christensen, G; Leistad, E; Verburg, E, 1996) |
| "Atrial contractile dysfunction after short-term atrial fibrillation is reduced by the calcium antagonist verapamil, which suggests that transsarcolemmal calcium influx contributed to this dysfunction." | 3.69 | Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. ( Aksnes, G; Christensen, G; Leistad, E; Verburg, E, 1996) |
| "In patients with persistent atrial fibrillation (AF), the atrial myocardium is characterized by a reduced contractile force, by a shortened duration of the action potential and a recently demonstrated reduction of the L-type Ca2+ currents." | 1.31 | L-type calcium currents in atrial myocytes from patients with persistent and non-persistent atrial fibrillation. ( Jüngling, E; Lückhoff, A; Picht, E; Schöndube, F; Skasa, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chahine, M | 1 |
| Qu, Y | 1 |
| Mancarella, S | 1 |
| Boutjdir, M | 1 |
| Leistad, E | 1 |
| Aksnes, G | 1 |
| Verburg, E | 1 |
| Christensen, G | 1 |
| Schotten, U | 1 |
| Ausma, J | 1 |
| Stellbrink, C | 1 |
| Sabatschus, I | 1 |
| Vogel, M | 1 |
| Frechen, D | 1 |
| Schoendube, F | 1 |
| Hanrath, P | 1 |
| Allessie, MA | 1 |
| Skasa, M | 1 |
| Jüngling, E | 1 |
| Picht, E | 1 |
| Schöndube, F | 1 |
| Lückhoff, A | 1 |
| Anyukhovsky, EP | 1 |
| Sosunov, EA | 1 |
| Plotnikov, A | 1 |
| Gainullin, RZ | 1 |
| Jhang, JS | 1 |
| Marboe, CC | 1 |
| Rosen, MR | 1 |
5 other studies available for bay-k-8644 and Auricular Fibrillation
| Article | Year |
|---|---|
Protein kinase C activation inhibits alpha1D L-type Ca channel: a single-channel analysis.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2008 |
Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1996 |
Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2001 |
L-type calcium currents in atrial myocytes from patients with persistent and non-persistent atrial fibrillation.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2001 |
Cellular electrophysiologic properties of old canine atria provide a substrate for arrhythmogenesis.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2002 |